6-K filed May 12, 2026 at 07:08 ET
Immatics reported Q1 2026 financial results showing a net loss of €57.8 million ($66.5 million) on revenue of €7.6 million ($8.7 million), compared to a net loss of €39.9 million on revenue of €18.6 million in Q1 2025. Revenue declined 59% YoY due to lower cost recognition on collaboration agreements, while R&D expenses surged 41% to €59.2 million driven by the SUPRAME Phase 3 trial. Cash and equivalents plus other financial assets stood at €453.6 million ($521.5 million), with cash runway projected into 2028. The company reiterated key 2026 catalysts including SUPRAME interim/final analysis triggers and multiple ASCO data presentations, but the widening operating loss and revenue decline overshadow pipeline progress.